EFTR Stock Price, eFFECTOR Therapeutics, . Quote, Chart

Market Summary

USD1.78-0.11

Market Closed

-5.82%

EFTR Stock Price

View Fullscreen

EFTR RSI Chart

EFTR Valuation

Market Cap

6.6M

Price/Earnings (Trailing)

-0.18

Price/Sales (Trailing)

2.25

EV/EBITDA

0.64

Price/Free Cashflow

-0.22

EFTR Price/Sales (Trailing)

EFTR Profitability

EBT Margin

427.69%

Return on Equity

617.96%

Return on Assets

-174.31%

Free Cashflow Yield

-450.22%

EFTR Fundamentals

EFTR Revenue

Revenue (TTM)

3.9M

EFTR Earnings

Earnings (TTM)

-35.8M

Earnings Growth (Yr)

1.4%

Earnings Growth (Qtr)

-9.96%

Breaking Down EFTR Revenue

Last 7 days

-20.2%

Last 30 days

-85.5%

Last 90 days

-83.2%

Trailing 12 Months

-82.2%

How does EFTR drawdown profile look like?

EFTR Financial Health

Current Ratio

0.77

Debt/Equity

-3.24

Debt/Cashflow

-1.58

EFTR Investor Care

Shares Dilution (1Y)

54.26%

Diluted EPS (TTM)

-16.5

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q2	Q3	Q4
2023	0	0	0
2022	2.5M	3.6M	3.9M
2021	28.5M	15.0M	1.4M
2020	0	0	42.0M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of eFFECTOR Therapeutics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Nov 27, 2023	sr one capital management, llc	sold	-108,312	0.6065	-178,585	-
Nov 27, 2023	sr one capital management, llc	sold	-261,146	0.6065	-430,578	-
Nov 15, 2023	byrnes michael	acquired	2,249	0.4973	4,524	chief financial officer
Nov 15, 2023	worland stephen t	acquired	2,973	0.4973	5,979	chief executive officer
Aug 11, 2023	worland stephen t	acquired	17,575	0.52	33,799	chief executive officer
May 15, 2023	byrnes michael	acquired	2,232	0.459	4,863	chief financial officer
May 15, 2023	worland stephen t	acquired	2,938	0.459	6,401	chief executive officer
Nov 15, 2022	byrnes michael	acquired	2,178	0.4684	4,651	chief financial officer
Nov 15, 2022	worland stephen t	acquired	2,832	0.4684	6,047	chief executive officer
Oct 04, 2022	ehrlich christopher b	bought	197	0.57	346	-

Which funds bought or sold EFTR recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Mar 11, 2024	VANGUARD GROUP INC	added	42.17	26,106	268,481	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	added	100	43,003	90,924	-%
Mar 01, 2024	Pineridge Advisors LLC	new	-	2.00	2.00	-%
Feb 28, 2024	EP Wealth Advisors, LLC	sold off	-100	-18,597	-	-%
Feb 15, 2024	BARCLAYS PLC	sold off	-100	-	-	-%
Feb 14, 2024	TWO SIGMA SECURITIES, LLC	new	-	28,836	28,836	-%
Feb 14, 2024	Blackstone Inc.	unchanged	-	-173,387	611,634	-%
Feb 14, 2024	Royal Bank of Canada	reduced	-64.29	-	-	-%
Feb 14, 2024	ARISTEIA CAPITAL, L.L.C.	reduced	-0.01	-2,923	158,353	-%
Feb 14, 2024	WHITEBOX ADVISORS LLC	unchanged	-	21,317	43,976	-%

Are Funds Buying or Selling EFTR?

Are funds buying EFTR calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own EFTR

No. of Funds

Unveiling eFFECTOR Therapeutics, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	sectoral asset management inc	3.7%	2,382,644	SC 13G/A
Feb 14, 2024	pfizer inc	3.47%	2,243,850	SC 13G/A
Feb 09, 2024	sr one capital management, llc	0%	0	SC 13G/A
Feb 05, 2024	altitude life science ventures fund ii, l.p.	2.2%	1,413,175	SC 13G/A
Nov 22, 2023	column group ii, lp	0%	0	SC 13D/A
Sep 15, 2023	column group ii, lp	6.6%	4,091,734	SC 13D/A
Aug 18, 2023	carlyle group inc.	7.8%	4,829,891	SC 13D/A
Mar 07, 2023	altitude life science ventures fund ii, l.p.	3.4%	1,413,175	SC 13G
Feb 14, 2023	empyrean capital partners, lp	0%	0	SC 13G/A
Feb 13, 2023	sectoral asset management inc	5.7%	2,382,644	SC 13G/A

Recent SEC filings of eFFECTOR Therapeutics, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 16, 2024	PRE 14A	PRE 14A
Apr 04, 2024	424B3	Prospectus Filed
Apr 04, 2024	424B5	Prospectus Filed
Apr 04, 2024	8-K	Current Report
Apr 02, 2024	EFFECT	EFFECT
Mar 29, 2024	POS AM	POS AM
Mar 28, 2024	S-8	Employee Benefits Plan
Mar 26, 2024	10-K	Annual Report
Mar 25, 2024	8-K	Current Report
Feb 21, 2024	4	Insider Trading

Peers (Alternatives to eFFECTOR Therapeutics, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	39.0B	6.8B	-2.93%	-28.56%	-8.27	5.69	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.3B	1.8B	-2.14%	-28.32%	-41.48	9.99	76.23%	61.08%
BMRN	17.0B	2.4B	5.64%	-9.07%	101.38	7.03	15.42%	18.43%
INCY	11.9B	3.7B	-9.46%	-28.45%	19.84	3.21	8.87%	75.42%
MID-CAP
APLS	5.7B	396.6M	-16.55%	-42.15%	-10.83	14.44	425.83%	18.94%
BBIO	4.4B	-	-12.14%	49.76%	-6.72	60.35	54.84%	-34.79%
AXSM	3.1B	270.6M	-14.48%	-8.88%	-13.02	11.51	440.80%	-27.84%
ACAD	2.8B	726.4M	-8.72%	-14.74%	-45.89	3.87	40.45%	71.62%
ARWR	2.8B	240.7M	-18.65%	-25.84%	-9.43	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-6.41%	-11.48%	25.32	4.54	85.90%	-14.05%
NVAX	544.4M	983.7M	-21.26%	-56.58%	-1	0.55	-50.36%	17.16%
CRBP	382.8M	881.7K	-14.69%	262.26%	-8.58	466.16	-77.61%	-5.33%
INO	238.4M	4.9M	-4.49%	-3.41%	-1.76	48.98	-54.97%	51.71%
IBIO	6.2M	2.1M	67.92%	36.92%	-0.23	2.14	-13.45%	66.37%

eFFECTOR Therapeutics, Inc. News

Latest updates

eFFECTOR Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2022Q4	2022Q3	2022Q2	2021Q4	2021Q3	2021Q2	2020Q4	2020Q3	2020Q2
Revenue	-100.0%	-	675,000	867,000	2,011,000	311,000	427,000	4,095,250	7,763,500	11,431,750	15,100,000
Operating Expenses	-8.5%	8,598,000	9,398,000	10,118,000	9,892,000	12,713,000	9,141,000	5,736,000	5,661,000	7,843,000	5,952,000
S&GA Expenses	-8.2%	2,524,000	2,748,000	3,486,000	2,973,000	6,319,000	4,119,000	1,664,000	1,060,000	1,063,000	1,126,000
R&D Expenses	-8.7%	6,074,000	6,650,000	6,632,000	6,919,000	6,394,000	5,022,000	4,072,000	4,601,000	6,780,000	4,826,000
EBITDA Margin	3.9%	5.06	4.87	5.14	7.33	12.81	-0.57	-0.31	-	-	-
Interest Expenses	8.7%	758,000	697,500	570,000	505,000	490,000	488,000	480,000	314,000	342,000	340,000
Income Taxes	-	-	-	-	-	-	-	-	-49,000	5,000	126,000
Earnings Before Taxes	-	-	-	-	-	19,049,000	8,879,000	-5,548,000	-5,854,000	-7,604,000	8,719,000
EBT Margin	0%	4.28	4.28	4.57	6.55	11.56	-0.68	-0.36	-	-	-
Net Income	1.4%	-9,130,000	-9,260,000	-9,559,000	-6,915,000	19,049,000	8,879,000	-5,548,000	-5,854,000	-7,609,000	8,593,000
Net Income Margin	-58.0%	-9.27	-5.87	1.56	9.54	11.05	-0.61	-0.90	-	-	-
Free Cashflow	18.3%	-5,566,000	-6,816,000	-8,220,000	-4,474,000	-5,044,000	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet														(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2019Q4
Assets	1.9%	21.00	20.00	27.00	22.00	29.00	37.00	43.00	49.00	54.00	60.00	14.00	177	17.00	-
Current Assets	2.9%	20.00	19.00	26.00	21.00	28.00	36.00	42.00	48.00	53.00	59.00	12.00	2.00	17.00	4.00
Cash Equivalents	176.2%	15.00	5.00	15.00	10.00	9.00	12.00	16.00	18.00	50.00	55.00	11.00	17.00	15.00	3.00
Net PPE	-42.6%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00	0.00
Liabilities	9.2%	26.00	24.00	24.00	27.00	25.00	25.00	24.00	24.00	37.00	68.00	25.00	10.00	16.00	19.00
Current Liabilities	9.4%	26.00	24.00	24.00	27.00	25.00	25.00	24.00	3.00	4.00	46.00	5.00	0.00	9.00	19.00
Long Term Debt	-	-	-	-	-	-	-	-	-	19.00	19.00	19.00	-	7.00	-
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	-	-	-	6.00	15.00
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	19.00	19.00	19.00	-	7.00	-
Shareholder's Equity	-Infinity%	-5.79	-	3.00	-	4.00	12.00	20.00	25.00	17.00	-	5.00	5.00	0.00	-
Retained Earnings	-5.4%	-179	-170	-161	-153	-143	-134	-124	-117	-120	-140	-148	0.00	-136	-150
Additional Paid-In Capital	4.4%	174	166	165	149	147	146	144	143	138	132	5.00	5.00	4.00	4.00
Shares Outstanding	19.3%	3.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	0.00	0.00	0.00	0.00	-
Float	-	-	-	51.00	-	-	-	48.00	-	-	-	173	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2019Q4
Cashflow From Operations	28.2%	-5,566	-7,755	-8,592	-7,637	-6,780	-8,184	-4,438	-6,497	-5,008	-9,067	-5,816	-4,997	-1.07	-7,415	-	-
Share Based Compensation	-1.6%	1,124	1,142	1,162	1,167	1,386	1,569	1,241	1,138	5,926	2,385	161	188	155	156	-	-
Cashflow From Investing	567.2%	8,946	-1,915	-1,574	9,027	3,622	3,623	3,169	-28,274	-36.00	-6.00	-	607	-	-	-	-
Cashflow From Financing	1686.3%	6,109	342	14,570	212	-37.00	111	-42.00	2,733	-22.00	52,961	-78.00	5,948	13.00	-481	-	-

EFTR Income Statement

2023-12-31

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Grant revenue	$ 0	$ 3,553
Operating expenses:
Research and development	22,919	23,313
General and administrative	10,925	12,643
Total operating expenses	33,844	35,956
Operating (loss) income	(33,844)	(32,403)
Other income (expense)
Interest income	972	439
Interest expense	(2,919)	(2,251)
Other income (expense), net	(26)	(574)
Change in fair value of earn-out liability	6	12,124
Total other income (expense)	(1,967)	9,738
Net income (loss)	(35,811)	(22,665)
Comprehensive income (loss):
Net loss	(35,811)	(22,665)
Other comprehensive loss	18	(18)
Comprehensive income (loss):	$ (35,793)	$ (22,683)
Net income (loss) per share attributable to common shareholders:
Net income per share - Basic	$ (16.37)	$ (13.76)
Net income per share - diluted	$ (16.37)	$ (13.76)
Weighted-average common shares outstanding:
Weighted average common shares outstanding - basic	2,186,954	1,647,183
Weighted average common shares outstanding - diluted	2,186,954	1,647,183

EFTR Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($)
$ in Thousands

Dec. 31, 2023

Dec. 31, 2022

Current assets:

Cash and cash equivalents

$ 14,875

$ 8,708

Short-term investments

3,495

17,602

Prepaid expenses and other current assets

1,468

1,704

Total current assets

19,838

28,014

Property and equipment, net

140

241

Operating lease right-of-use assets

53

111

Other assets

513

711

Total assets

20,544

29,077

Current liabilities:

Accounts payable

2,330

1,486

Accrued expenses

2,921

3,368

Current term loans, net

19,385

19,061

Accrued final payment on term loans, current

1,100

Operating lease liabilities, current

60

Total current liabilities

25,796

25,075

Other accrued liabilities, non-current

503

0

Earn-out liability

0

6

Non current warrant liability

40

Non-current lease liabilities

0

60

Total liabilities

26,339

25,181

Commitments and contingencies

Stockholders' equity (deficit):

Preferred stock, $0.0001 par value; 100,000,000 and zero shares authorised at December 31, 2023 and December 31, 2022, respectively; zero shares issued and outstanding as of December 31, 2023 and December 31,2022

0

Common stock, $0.0001 par value; 1,000,000,000 shares authorized at December 31, 2023 and December 31, 2022; 41,990,383 shares issued and 41,690,383 shares issued and outstanding as of December 31, 2023; 40,689,975 shares issued and 40,3389,975 shares issued and outstanding as of December 31, 2022

^[1]

0

Additional paid-in capital

^[1]

173,582

147,480

Accumulated other comprehensive loss

0

(18)

Accumulated deficit

(179,377)

(143,566)

Total stockholders' equity (deficit)

(5,795)

3,896

Total liabilities and stockholders' equity (deficit)

$ 20,544

$ 29,077

[1]	Amounts have been retroactively restated to reflect the 1-for-25 reverse stock split effected on January 12, 2024 (see Note 1. Organization and Basis of Presentation of the accompanying notes to the consolidated financial statements).

About eFFECTOR Therapeutics, Inc.

eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors and in combination with fulvestrant and abemaciclib in a Phase 2a open-label expansion cohort to treat patients with ER+ breast cancer. eFFECTOR Therapeutics, Inc. has a research collaboration and license agreement with Pfizer Inc. to develop inhibitors of eIF4E. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.

CEO	Dr. Stephen T. Worland Ph.D.
WEBSITE	https://effector.com
INDUSTRY	Biotechnology
EMPLOYEES	15

eFFECTOR Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for eFFECTOR Therapeutics, Inc.? What does EFTR stand for in stocks?

EFTR is the stock ticker symbol of eFFECTOR Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of eFFECTOR Therapeutics, Inc. (EFTR)?

As of Thu Apr 18 2024, market cap of eFFECTOR Therapeutics, Inc. is 6.56 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of EFTR stock?

You can check EFTR's fair value in chart for subscribers.

What is the fair value of EFTR stock?

You can check EFTR's fair value in chart for subscribers. The fair value of eFFECTOR Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of eFFECTOR Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for EFTR so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is eFFECTOR Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether EFTR is over valued or under valued. Whether eFFECTOR Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact eFFECTOR Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for EFTR.

What is eFFECTOR Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Apr 18 2024, EFTR's PE ratio (Price to Earnings) is -0.18 and Price to Sales (PS) ratio is 2.25. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. EFTR PE ratio will change depending on the future growth rate expectations of investors.